Anemia management in HD patients has focused on the use of erythropoiesis-stimulating agents (ESA) and iron therapy, but, following concerns regarding the safety of using high doses of ESA to meet aggressive Hb targets that were raised by clinical trials such as NHS [3], CREATE [4], CHOIR [5, 6] and TREAT [7],interest in the use of intravenous (IV) iron therapy has increased [8, 9]. This evidence concerns the gene GSTM1 and anemia.